Filing Flows › Companies › Acadia Pharmaceuticals › Report card
Acadia Pharmaceuticals earnings report card
Every report on file against what analysts and the company itself expected, and what the stock did
Beat rate3 of 5 reports beat the EPS estimate
Acadia Pharmaceuticals (ACAD) beat the analysts' EPS estimate in 3 of its last 5 reports (60%), by +44.9% on average. On report days the stock moved 0.9% in either direction on median (largest 12.5%), rising 80% of the time; after a beat it rose 67% of the time.
Report by report
| Quarter | Reported | EPS est. | EPS reported | Surprise | Revenue reported | Stock, the day | vs market |
|---|---|---|---|---|---|---|---|
| Q3 2026 | Nov 4, 2026 | $0.18 | $0.31 | +69.9% | $342M | +3.3% | +6.1% |
| Q2 2026 | Aug 4, 2026 | $0.04 | $0.18 | n/m | $308M | +12.5% | +10.9% |
| Q1 2026 | May 6, 2026 | $0.08 | $0.02 | -75.2% | $268M | +0.9% | -0.1% |
| Q4 2025 | Feb 25, 2026 | $0.14 | $0.14 | -4.2% | $284M | +0.2% | -0.1% |
| Q3 2025 | Nov 5, 2025 | $0.15 | $0.42 | +189.0% | $279M | -0.9% | -0.2% |
Estimates and reported EPS are the Street's adjusted figures. Revenue reported is from the company's filing. The stock's move is close to close around the report date (the close before it to the close of the session after), against SPY for the market column.
Charts
The earnings-day move
Over 5 reports the stock moved 0.9% on median on the day (close to close), the largest move 12.5%.
After a beat the stock rose 67% of the time (3 beats); after a miss it fell 0% of the time (2 misses).
The next report: what to expect → Acadia Pharmaceuticals: every quarter →
Read automatically from SEC filings, earnings releases and public estimates; errors are possible. Not investment advice.